Injectable Verapamil Hydrochloride Recalled Due to Cross Contamination Risk
Zydus Pharmaceuticals is recalling Verapamil Hydrochloride Injection vials nationwide due to potential cross contamination with other products.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class III FDA recall for low-risk contamination without reported illnesses or injuries. Per the rubric, precautionary recalls without confirmed harm are classified as Moderate.
Plain-English summary
Zydus Pharmaceuticals (USA) Inc. is recalling Verapamil Hydrochloride Injection, USP 5 mg/2 mL (2.5 mg/mL), a calcium channel blocker medication administered intravenously, due to potential cross contamination with other products. Approximately 170,755 single-dose vials are affected, distributed nationwide in the United States.
The recalled product is identified by the following lot numbers and expiration dates: (a) Lots L300255 and L300262, expiring 07/31/2025; (b) Lot L300263, expiring 08/31/2025. The product is manufactured by Zydus Lifesciences Ltd. in Vadodara, India, and distributed by Zydus Pharmaceuticals (USA) Inc. in Pennington, New Jersey.
The Food and Drug Administration classified this recall as Class III.
The recalled product
- Product
- VERAPAMIL HYDROCHLORIDE (VERAPAMIL HYDROCHLORIDE)
- Brand
- VERAPAMIL HYDROCHLORIDE
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc
- Category
- Drug — Injectable
- Hazard
- cross-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot# (a) Lots L300255
- L300262
- Exp Date 07/31/2025
- (b)L300263
- Exp Date 08/31/2025
UPCs (2)
- 0370710164379
- 0370710164355
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · VERAPAMIL HYDROCHLORIDE
- ModerateFDA recalls Verapamil Hydrochloride injectable due to cross contamination
FDA (Drugs) · 2024-07-17
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27